AIDS Advocates Push U.S. To Spend 50% Of Funds On Treatment
This article was originally published in PharmAsia News
Executive Summary
Advocates also are not sure whether to push for a long-term PEPFAR reauthorization; the U.S. expects to release a PEPFAR spending blueprint along with future goals shortly.
You may also be interested in...
FDASIA Is Signed, Not That White House Wanted Anyone To Notice
White House sends out short press release as FDA is conducting an unrelated briefing to announce the user fee bill was enacted, surprising stakeholders and generating political questions.
User Fee Bill Reemerges In Senate With Minor Tweaks, But More Changes Expected
The new bill includes a provision requiring FDA to consider foreign clinical trial data when making approval decisions and more patient participation in drug development meetings. A cloture vote could come as soon as May 17 with floor debate possibly beginning next week, Sen. Reid says.
NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System
The group is afraid asking for wholesale changes to the law would invite too many problems, VP Dorman says at BIO.